#neuromuscular-diseases

[ follow ]
#sarepta-therapeutics #sirna-programs #clinical-data #stock-market #aging-research #david-sinclair
Medicine
from24/7 Wall St.
1 week ago

Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?

Sarepta Therapeutics' stock surged 20% after releasing promising clinical data for two siRNA programs targeting rare neuromuscular diseases.
fromHarvard Gazette
9 months ago

Young researcher's ALS attack plan is now a no-go - Harvard Gazette

Rich is particularly drawn to Sinclair's approach, as it's unique and challenging conventional thought in medicine on how to address aging-related diseases comprehensively.
SF politics
[ Load more ]